Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Whole exome sequencing provides clues about rare mutations in aneurysms

An innovative approach to genome screening has provided clues about rare mutations that may make people susceptible to brain aneurysms, predisposing them to brain bleeds, according to preliminary late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

G-CSF's AX200 does not improve stroke-related disability

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

Soon therapies may be guided by genetic blueprints

In a futuristic bid the doctors have drawn up plans to sequence the full genetic code of thousands of people in a landmark project to personalize their medical care. Each person will have all 6 billion letters of their genome read, stored and linked to their medical records to help doctors prescribe more effective drugs and other therapies.

1 Jan 2012

Meta-analysis does not find significant association between CYP2C19 genotype and cardiovascular events

Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events.

28 Dec 2011

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

Tripling clopidogrel dosage improves platelet reactivity in cardiac patients

Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA.

17 Nov 2011

Drug-coated balloon restores blood flow in narrowed bare metal stent

A drug-coated balloon inserted in a narrowed bare metal stent is a promising therapy for restoring blood flow, according to research presented at the American Heart Association's Scientific Sessions 2011.

17 Nov 2011

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

Researchers examine optimal timing for carotid artery stenting after TIA or stroke

A recent study found no significant difference in the outcome for patients who received carotid artery stenting (CAS) at more than 30 days post-transient ischemic attack (TIA) or stroke versus those who received CAS at 30 days or less post-event.

15 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

10 Nov 2011

Clinical and genetic risk factors associated with early stent thrombosis

Patients with certain genes or specific factors related to use of the anti-clotting drug clopidogrel are more likely to experience a blood clot within a coronary stent shortly after placement, according to a study in the October 26 issue of JAMA.

27 Oct 2011

Scientists discover gene variants that contribute to early stent thrombosis

In a first-of-its-kind study, researchers from Mount Sinai School of Medicine have discovered several gene variants contributing to early stent thrombosis (ST), a devastating and often deadly complication after coronary stent implantation in people with coronary artery disease.

27 Oct 2011

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year. The new guideline suggests use of preventive treatments and advises against routinely screening patients after surgery using ultrasound imaging.

1 Oct 2011

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

The Venous Disease Coalition (VDC) and Peripheral Arterial Disease Coalition presented their annual research awards at the Vascular Disease Foundation's eighth annual meeting in Washington.

30 Sep 2011

Clopidogrel News and Research

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

Whole exome sequencing provides clues about rare mutations in aneurysms

Aspirin and warfarin similar in preventing deaths and strokes in heart failure patients

G-CSF's AX200 does not improve stroke-related disability

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

Soon therapies may be guided by genetic blueprints

Meta-analysis does not find significant association between CYP2C19 genotype and cardiovascular events

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

NYU Langone cardiovascular experts present new research findings at AHA 2011

Tripling clopidogrel dosage improves platelet reactivity in cardiac patients

Drug-coated balloon restores blood flow in narrowed bare metal stent

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

Researchers examine optimal timing for carotid artery stenting after TIA or stroke

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Clinical and genetic risk factors associated with early stent thrombosis

Scientists discover gene variants that contribute to early stent thrombosis

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News